Chromogranins from Cell Biology to Physiology and Biomedicine

264

High performance liquid chromatography
(HPLC), 214
Histamine, 161
Host defense peptides (HDPs), 50, 51
Human chromogranin A (CHGA) gene, SNPs
autonomic activity and blood pressure
CHGA promoter SNPs, 201–202
CHGA 3'-UTR, 202–203
catecholamines, 196
functional genetic polymorphisms
CST domain, 206–208
PST domain, 204–205
functional genetic variations, 197, 201
gene regulatory regions, discovery of,
197–199
haplotype distribution, 200
hypertensive nephrosclerosis, 203–204
resequencing strategy and identified
variants in, 198
systematic polymorphism, 197
Human umbilical vein endothelial cells
(HUVECs), 86, 108
Hypertension
catestatin, 151
human CHGA gene, SNPs in (see (Single
nucleotide polymorphisms (SNPs),
human CHGA gene))
Hypertensive nephrosclerosis, 203–204
Hypothalamus-pituitary-adrenal (HPA)
axis, 101

I
Implantable medical devices, 62
Innate immune system, 5, 50, 51
Inositol 1,4,5-trisphosphate receptor (IP 3 R)/
Ca2+ channel, chromogranins
A and B
endoplasmic reticulum, 70, 76, 77
intraluminal L3-2 loops
conserved amino acid sequences,
70–73
near C-terminal end, 70–72
pH-dependent interaction, 70, 74–76
IP 3 -induced Ca2+ release in
cytoplasm, 78
nonsecretory NIH3T3 cells, nucleus of,
78–79
nucleoplasmic Ca2+ store vesicles,
70, 77, 79
organelles, 77
secretory granules, 70, 76, 77
Irritable bowel syndrome (IBS), 44

Ischemia/reperfusion injury (IRI), CgA

derived peptides

apoptosis, 172, 175

autophagy, 172

Ca2+ overload phenomenon, 174

complex biochemical and mechanical

mechanisms, 172

inflammatory process, 175

mPTP, 174

myocardial ischemia, 173

necrosis, 172, 175

NFκB, 175

nitric oxide, 173–175

no-reflow phenomenon, 175

oxidative stress, 173, 174

peroxynitrite, 174

ROS/RNS, 173, 175

Ischemic preconditioning (IP), 175–178, 183

Isoproterenol (ISO), 116–118, 136–137

J

Janus Kinase (JAK), 178

L

Langerhans islet beta cells, 233

Large dense core vesicles (LDCVs), 252–257

Left ventricular pressure (LVP), 116

Lethal myocardial reperfusion injury, 172

Linkage disequilibrium (LD), 199

Luciferase reporter assay, 221

Lymphoma, 91

M

Mastoparan, 233

Matrix assisted laser desorption/ionization

time of flight (MALDI-TOF)

analysis, 214, 215

Mediation phase, 177

Memory phase, 177

Mercaptopropionyl glycine (MPG), 176

Metabolic disorders, 44

Microsequencing technique, 239

Mitochondrial membrane potential (MMP), 163

Mitochondrial permeability transition pore

(mPTP), 173

Mitogen activated protein kinase (MAPK),

234, 238

Molecular heterosis, 202

Monocyte chemoactractant

protein (MCP)-1, 86

Index